Get the Stockscreener App
3.20
3.32%
-0.11
After Hours:
3.19
-0.01
-0.31%
Aclarion Inc stock is traded at $3.20, with a volume of 67,618.
It is down -3.32% in the last 24 hours and down -10.36% over the past month.
Aclarion Inc is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (MRS), and a proprietary biomarker to optimize clinical treatments. Its product Nociscan is a SaaS platform that leverages MR Spectroscopy to noninvasively help physicians distinguish between painful and nonpainful discs in the spine. The company derives its revenues from one source, the delivery of Nociscan reports to medical professionals. Substantially all revenues are generated from contracts with customers in the United States.
See More
Previous Close:
$3.31
Open:
$3.27
24h Volume:
67,618
Relative Volume:
0.65
Market Cap:
$7.88M
Revenue:
$75,700
Net Income/Loss:
$-7.23M
P/E Ratio:
-0.186
EPS:
-17.2081
Net Cash Flow:
$-7.37M
1W Performance:
-5.04%
1M Performance:
-10.36%
6M Performance:
-57.33%
1Y Performance:
-55.24%
1-Day Range:
$3.20
$3.30
1-Week Range:
$3.20
$3.46
52-Week Range:
$2.3401
$12.03
Aclarion Inc Stock (ACON) Company Profile
Name
Aclarion Inc
Sector
Industry
Phone
833 275 2266
Address
8181 ARISTA PLACE, BROOMFIELD
Compare ACON vs VEEV, BTSG, TEM, HQY, DOCS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ACON
Aclarion Inc
|
3.20 | 8.15M | 75,700 | -7.23M | -7.37M | -17.21 |
VEEV
Veeva Systems Inc
|
171.19 | 27.80B | 3.20B | 908.91M | 1.39B | 5.4168 |
BTSG
Brightspring Health Services Inc
|
51.44 | 10.38B | 13.65B | 169.86M | 412.12M | 1.0758 |
TEM
Tempus Ai Inc
|
54.07 | 10.01B | 1.27B | -245.03M | -245.36M | -1.4071 |
HQY
Healthequity Inc
|
82.63 | 6.94B | 1.31B | 215.20M | 408.32M | 2.4627 |
DOCS
Doximity Inc
|
25.77 | 4.60B | 637.78M | 239.40M | 307.21M | 1.1909 |
Aclarion Inc Stock (ACON) Latest News
Aclarion establishes second trial agreement with Weill Cornell By Investing.com - Investing.com Canada
Aclarion announces second commercial agreement with Weill Cornell Medicine - marketscreener.com
Weill Cornell adds Aclarion scan to 2-year spine surgery trial - Stock Titan
Aclarion Announces Second Commercial Agreement with Weill Cornell Medicine - The Manila Times
Aclarion announces $2.5M stock repurchase plan - MSN
Aclarion reports cash runway to ops into late 2027 - BizWest
Aclarion Reports 196% Annual Scan Volume Growth in Q1 2026, Fueled by Accelerating Clinical Adoption of Nociscan - MEXC Exchange
Aclarion reports 196% jump in Nociscan scan volumes in Q1 - Investing.com UK
Aclarion reports 196% jump in Nociscan scan volumes in Q1 By Investing.com - Investing.com Australia
Aclarion Delivers Strong Q1 2026 Results with 196% Annual Scan Volume Growth Reflecting Accelerating Clinical Adoption - The Manila Times
Back-pain scan use rose 196% as Aclarion funds operations into 2027 - Stock Titan
Aclarion names Daniel Keefe as commercial director for Western US - Medical Buyer
Aclarion Appoints Daniel Keefe as Commercial Director, Western U.S., to Drive Continued ... - Bluefield Daily Telegraph
Aclarion, Inc. Appoints Daniel Keefe as Commercial Director, Western U.S - marketscreener.com
Aclarion (NASDAQ: ACON) expands 2022 equity plan in 2026 shareholder proxy - Stock Titan
Aclarion authorizes $2.5 million share buyback program By Investing.com - Investing.com India
Aclarion Launches $2.5 Million Share Repurchase Program - The Globe and Mail
Aclarion Announces $2.5 Million Stock Repurchase Plan - Ortho Spine News
Aclarion, Inc. announces an Equity Buyback for $2.5 million worth of its shares. - marketscreener.com
Aclarion authorizes $2.5 million share buyback program - Investing.com
Aclarion authorizes $2.5M share repurchase plan to deploy cash and support Nociscan growth - TradingView
Aclarion (NASDAQ: ACON) launches $2.5M share buyback plan - Stock Titan
With $19M cash, Aclarion plans buybacks while funding Nociscan - Stock Titan
Aclarion, Inc. authorizes a Buyback Plan. - marketscreener.com
Aclarion (ACON) Stock Insider Buying (Eye on Rally) 2026-04-20Community Watchlist - Xã Vĩnh Công
Aclarion receives patent for AI-based pain evaluation platform By Investing.com - Investing.com India
Aclarion Secures U.S. Patent Advancing Scalable, AI-Driven Assessment of Chronic Low Back Pain - The Manila Times
Aclarion receives patent for AI-based pain evaluation platform - Investing.com
Aclarion, Inc. Secures U.S. Patent for AI-Enhanced Machine Learning Platform in Chronic Low Back Pain Diagnosis - Quiver Quantitative
New Aclarion patent targets faster, more consistent chronic back-pain scans - Stock Titan
Aclarion (ACON) Stock Conversion (Momentum Building) 2026-04-15Long Term Investing - Xã Vĩnh Công
Aclarion's AI Platform Nociscan Wins Pinnacle Award, Validating Approach to Chronic Low Back Pain Diagnosis - citybuzz -
Aclarion Receives Pinnacle Award for AI Innovation - The Manila Times
AI tool for chronic back pain earns Aclarion a second health tech award - Stock Titan
Aclarion (ACON) price target decreased by 69.57% to 7.14 - MSN
Take Profit: Will Opendoor Technologies Inc outperform the market in YEAR2026 Trading Recap & Verified Swing Trading Watchlist - baoquankhu1.vn
Will Aclarion (ACON) Stock Go Higher | Price at $3.80, Up 6.44%Seasonal Patterns - Cổng thông tin điện tử tỉnh Lào Cai
Aclarion Announces Agreement with Weill Cornell Medicine - Bitget
Aclarion establishes agreement with Weill Cornell Medicine By Investing.com - Investing.com Australia
Aclarion Partners with Weill Cornell Medicine to Expand Nociscan Use in Spine Pain Research - citybuzz -
Aclarion establishes agreement with Weill Cornell Medicine - Investing.com
Aclarion Inc Stock (ACON) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.66%
1.60%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):